Kondo A, Mogi M, Koshihara Y, Togari A
Department of Pharmacology, School of Dentistry, Aichi-Gakuin University, 464-8650, Nagoya, Japan.
Biochem Pharmacol. 2001 Feb 1;61(3):319-26. doi: 10.1016/s0006-2952(00)00544-x.
Epinephrine increased gene- and protein-expression of interleukin-6 (IL-6) and interleukin-11 (IL-11), which are capable of stimulating the development of osteoclasts from their hematopoietic precursors, in human osteoblast (SaM-1) and human osteosarcoma (SaOS-2, HOS, and MG-63) cell lines. An increase in IL-6 and IL-11 synthesis in response to epinephrine appeared to be a common feature in osteoblastic cells, but the magnitude of expression was different in these cell lines. In HOS cells treated with epinephrine, increases of IL-6 and IL-11 synthesis were inhibited by timolol (a beta-blocker), H-89 (N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide; an inhibitor of protein kinase A (PKA)) and SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole; an inhibitor of p38 mitogen-activated protein kinase (MAPK)], but not by phentolamine (an alpha-blocker), calphostin C [an inhibitor of protein kinase C (PKC)], or PD98059 (2'-amino-3'-methoxyflavone; an inhibitor of classic MAPK), suggesting a common pathway mediated by beta-adrenergic receptors in the PKA and p38 systems involved in the signal transduction of IL-6 and IL-11. Furthermore, expression of both genes was inhibited by curcumin [an inhibitor of activating protein-1 (AP-1) activation], but not by pyrrolidine dithiocarbamate (PDTC) [an inhibitor of nuclear factor (NF)-kappaB]. The pharmacological study suggested that coinduction of the two genes in response to epinephrine occurred via activation of AP-1. The findings of the present study suggest that coinduction of IL-6 and IL-11 in response to epinephrine probably occurs via the PKA and p38 MAPK systems, leading to the transcriptional activation of AP-1 in human osteoblastic cells.
肾上腺素可增加人成骨细胞(SaM-1)以及人骨肉瘤细胞系(SaOS-2、HOS和MG-63)中白细胞介素-6(IL-6)和白细胞介素-11(IL-11)的基因和蛋白表达,而这两种细胞因子能够刺激破骨细胞从其造血前体发育而来。响应肾上腺素时IL-6和IL-11合成增加似乎是成骨细胞的一个共同特征,但这些细胞系中表达的程度有所不同。在用肾上腺素处理的HOS细胞中,噻吗洛尔(一种β受体阻滞剂)、H-89(N-[2-((对溴肉桂基)氨基)乙基]-5-异喹啉磺酰胺;蛋白激酶A(PKA)抑制剂)和SB203580 [4-(4-氟苯基)-2-(4-甲亚磺酰基苯基)-5-(4-吡啶基)1H-咪唑;p38丝裂原活化蛋白激酶(MAPK)抑制剂]可抑制IL-6和IL-11合成的增加,但酚妥拉明(一种α受体阻滞剂)、钙泊三醇C [蛋白激酶C(PKC)抑制剂]或PD98059(2'-氨基-3'-甲氧基黄酮;经典MAPK抑制剂)则不能,这表明在参与IL-6和IL-11信号转导的PKA和p38系统中,由β肾上腺素能受体介导的一条共同途径。此外,姜黄素[激活蛋白-1(AP-1)激活抑制剂]可抑制这两种基因的表达,但吡咯烷二硫代氨基甲酸盐(PDTC)[核因子(NF)-κB抑制剂]则不能。药理学研究表明,响应肾上腺素时这两种基因的共同诱导是通过AP-1的激活而发生的。本研究结果表明,响应肾上腺素时IL-6和IL-11的共同诱导可能是通过PKA和p38 MAPK系统发生的,从而导致人成骨细胞中AP-1的转录激活。